of borderline significanceP = 0.056
At 9.7 years median follow-up, multivariate analysis showed a DFS benefit for tamoxifen of borderline significance ( P = 0.056) and a trend for improved OS ( P = 0.12).
At 9.7 years median follow-up, multivariate analysis showed a DFS benefit for tamoxifen of borderline significance ( P = 0.056) and a trend for improved OS ( P = 0.12).